Spectoliphen 100 222 mg/g Poeder voor gebruik in drinkwater
Spectoliphen 100 222 mg/g Poeder voor gebruik in drinkwater
Authorised
- Lincomycin hydrochloride
- Spectinomycin sulfate tetrahydrate
Product identification
Medicine name:
Spectoliphen 100 222 mg/g Poeder voor gebruik in drinkwater
Active substance:
- Lincomycin hydrochloride
- Spectinomycin sulfate tetrahydrate
Target species:
-
Chicken
-
Pig
Route of administration:
-
In drinking water use
Product details
Active substance and strength:
-
Lincomycin hydrochloride241.90/milligram(s)1.00gram(s)
-
Spectinomycin sulfate tetrahydrate671.30/milligram(s)1.00gram(s)
Pharmaceutical form:
-
Powder for use in drinking water
Withdrawal period by route of administration:
-
In drinking water use
-
Chicken
-
Meat and offal4dayDuring treatment, animals should not be slaughtered for human consumption.
-
Eggno withdrawal periodDo not use in animals producing eggs for human consumption
-
-
Pig
-
Meat and offal3dayDuring treatment, animals should not be slaughtered for human consumption.
-
-
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QJ01FF52
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
Belgium
Available in:
-
Belgium
Package description:
- Spectoliphen 100 Jar with 4.5 kg Powder for use in drinking water
- Spectoliphen 100 Jar with 3 kg Powder for use in drinking water
- Spectoliphen 100 Jar with 1.5 kg Powder for use in drinking water
- Spectoliphen 100 Jar with 150 g Powder for use in drinking water
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
- KELA Kempisch Laboratorium Kela Laboratoria
Marketing authorisation date:
Manufacturing sites for batch release:
- KELA Kempisch Laboratorium Kela Laboratoria
Responsible authority:
- Federal Agency For Medicines And Health Products
Authorisation number:
- BE-V142721
Date of authorisation status change:
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Summary of Product Characteristics
This document does not exist in this language (English). You can find it
in another language below.
Package Leaflet
This document does not exist in this language (English). You can find it
in another language below.
Labelling
This document does not exist in this language (English). You can find it
in another language below.
